2021 BCMA-Directed Therapies in Multiple Myeloma

December 4, 2021

2021 BCMA Directed Therapies in Multiple Myeloma, is a CME-accredited, half-day conference featuring leading experts in multiple myeloma who will provide a comprehensive overview of current state and the future implications of B-cell Maturation Antigen (BCMA) directed therapies in multiple myeloma (MM). The goal of this activity is to improve the knowledge and the competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with MM. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in MM focusing on multiple immunotherapeutic options with BCMA as the lead target. Expert faculty will utilize didactics, case-based presentations, and related panel discussions on several current and emerging BCMA directed therapies including bispecific antibodies, CART and ADC available for MM patients, and how to sequence them in an effective manner to provide the best outcomes. The Binaytara Foundation will utilize a virtual format that includes both online recorded materials and live web-based interactive discussions to provide an easily accessible environment for learning, engagement, and dialogue with peers and presenters. 

Target Audience

  • Cancer care professionals
  • Practicing hematologists and oncologists
  • Oncology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review the mechanism of resistance and determinants of response to BCMA directed therapies
  • Describe the role, including efficacy and adverse events, of BCMA-directed CAR-T therapy in MM
  • Outline the role, including efficacy and adverse events, of BMCA directed BsB and ADC in MM.
  • Integrate BCMA directed therapies in the management of relapsed and/or refractory MM
  • Identify and manage adverse events from BCMA directed therapies
Course summary
Available credit: 
  • 2.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 2.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 2.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.50 Contact Hours.
Course opens: 
10/07/2021
Course expires: 
01/04/2022
Event starts: 
12/04/2021 - 7:00am PST
Event ends: 
12/04/2021 - 11:00am PST
Cost:
$1.00
Add to calendar: 

Conference Chair: Binod Dhakal, MD, MS

All times below are listed in Pacific Standard Time

7:15AM - 8:00AM PST: Registration/Networking 

Moderator: Dinesh Bhurani, MBBS, MD, DM, FRCPA

8:00AM - 8:30AM PST: BCMA CAR-T in MM: Current state and future implications - Adam Sperling, MD, PhD

8:30AM - 9:00AM PST: Role of BCMA bispecific antibodies in MM - Alfred L. Garfall, MD

9:00AM - 9:30AM PST: BREAK

 Moderator: Dinesh Bhurani, MBBS, MD, DM, FRCPA

9:30AM - 10:00AM PST: Optimal sequencing of CAR-T vs. bispecific antibodies and other immune therapies in MM - Surbhi Sidana, MD 

10:00AM - 10:30AM PST: Understanding the determinants of response and mechanism of resistance to BCMA targeted agents - Krina Patel, MD, MSc

10:30AM - 11:00AM PST: Case-based discussion - Binod Dhakal, MD, MS

11:00AM: ADJOURN

Speaker/Topic Presenter(s)

Binod Dhakal, MD, MS

has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with GSK;.
has a financial relationship (Other) with Natera;.
has a financial relationship (Other) with Celgene/BMS;.
has a financial relationship (Other) with Sanofi;.

Alfred Garfall, MD

has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Tmunity;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with CRISPR Therapeutics;.

Krina Patel, MD

has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Legend Biotech;.

Surbhi Sidana, MD

has a financial relationship (Professional Services) with Magenta Therapeutcs, BMS, Janssen, Sanofi, Oncopeptides;.
has a financial relationship (Grant Or Contract) with Magenta Therapeutics, BMS, Allogene, Janssen;.

Adam Sperling, MD, PhD

has a financial relationship (Other) with Adaptive;.
Moderator(s)

DINESH BHURANI, Dr. Dinesh Bhurani

has no relevant financial relationships to disclose at this time.

Available Credit

  • 2.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 2.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 2.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.50 Contact Hours.

All Virtual Exhibits and product theaters include the following benefits:

  • A dedicated presentation slot depending on the level of sponsorship. 
  • A company named breakout room
  • Registration for company representatives
  • Company name with product link on conference exhibit page (information provided by company) 

 

Complete the exhibit/product theater form below to exhibit at this meeting:

 

Price

Cost:
$1.00
Please login or register to take this course.

Registration

This webinar is free for health care providers.

If you are employed by the industry, you must register as "Industry representative" even if you are a licensed healthcare provider not involved in the sales of product. The industry price is applicable to everyone who are employed by an ACCME defined ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients.

Cancellation Policy 

You may cancel your enrollment at any time. 

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.